Heroin addiction is an epidemic. This puts Amphastar Pharmaceuticals, Inc. (AMPH) in the spotlight.The fair value of AMPH is $28.30, implying upside of up to ~67%. Click here to enter your assumptions.AMPH reported Q1 profits of $893K ($0.02 per share) on revenue of $56.7M. Though sales of epinephrine improved to $9.6M from $4.4M, use of rebates hurt the ASP. If the FDA grants a grandfather exception to the USP vial product for epinephrine, AMPH revenue will hold. The other positive catalysts are the 6 ANDA filings with the FDA. Per the ER: ® Mist and intranasal naloxone. The Company is currently developing four other proprietary products, which include injectable, inhalation and intranasal dosage forms." data-reactid="39" style="margin: 0.8em 0px 0px; color: rgb(38, 40, 42); font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; background-color: rgb(255, 255, 255);">The Company currently has six abbreviated new drug applications, or ANDAs filed with the FDA, targeting products with a market size of over $1.1 billion, three biosimilar products in development targeting products with a market size of $15.0 billion, and 11 generic products in development targeting products with a market size of over $12.0 billion. This market information is based on IMS Health data for the 12 months ended March 31, 2017. $AMPH, Amphastar Pharmaceuticals, Inc. / D